CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)			3 Months Ended			12 Months Ended
	Jul. 11, 2022 USD ($)	Feb. 17, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) Director	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Total debt						$ 549,704,000	$ 433,484,000
Net loss attributable to noncontrolling interests						$ (6,341,000)	$ (102,983,000)	$ (69,412,000)
Entasis Therapeutics Holdings Inc
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares					14,000,000
Number of investee's board members which may be designated by the Company | Director						2
Payments to acquire equity securities			$ 20,000,000.0
Remeasurement loss						$ 7,800,000
Payment towards convertible promissory note	$ 0
Measurement period adjustments for change in value of goodwill						(4,700,000)
Measurement period adjustments for change in estimated purchase price						(1,400,000)
Measurement period adjustments for change in value of noncontrolling interests						1,700,000
Measurement period adjustments for change in value of intangible assets						2,500,000
Net loss attributable to noncontrolling interests						$ 13,600,000
Business Acquisitions of Change in Fair Value of Investment	$ 1,400,000
Entasis Therapeutics Holdings Inc | Consolidated Investees
Subsidiary or Equity Method Investee [Line Items]
Equity method investment ownership percentage		59.90%
Entasis Therapeutics Holdings Inc | Securities purchase agreement | Convertable promissory note
Subsidiary or Equity Method Investee [Line Items]
Total debt		$ 15,000,000.0
Debt Instrument, annual interest rate		0.59%
Debt instrument maturity date		Aug. 18, 2022
Conversion price (dollars per share) | $ / shares		$ 1.48
Entasis Therapeutics Holdings Inc | Common stock
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares				4,672,897
Fair value of equity securities		$ 64,500,000
Entasis Therapeutics Holdings Inc | Common stock | Innoviva Strategic Opportunities, LLC
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares			10,000,000
Entasis Therapeutics Holdings Inc | Warrants
Subsidiary or Equity Method Investee [Line Items]
Number of warrants purchased under the securities purchase agreement | shares				4,672,897	14,000,000
Fair value of equity securities		$ 31,400,000
Entasis Therapeutics Holdings Inc | Warrants | Innoviva Strategic Opportunities, LLC
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares			10,000,000
Entasis Therapeutics Holdings Inc | Common stock and warrants
Subsidiary or Equity Method Investee [Line Items]
Payments to acquire equity securities				$ 12,500,000	$ 35,000,000.0
Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2021
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares			$ 2.00
Term of warrants						5 years
Entasis Therapeutics Holdings Inc | Warrants acquired in third quarter of 2020
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares				$ 2.675
Term of warrants						5 years
Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2020
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares					$ 2.50
Term of warrants						5 years